ImmunoCellular Receives Japanese Patent For ICT-109

ImmunoCellular (IMUC) has reported the issuance of a Japanese patent relating to the company’s monoclonal antibody therapeutics.

Patent No. 4287147 is titled Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment of Small Cell Lung Cancer. It covers the use of IMUC’s proprietary antibodies in diagnosing and treating patients with small cell lung cancer (SCLC), using the company’s lead antibody product candidate, ICT-109.

Manish Singh, President and CEO of IMUC, said: The Japanese patent office’s recognition of the unique nature of the potential therapeutic benefits of our antibody technology for early diagnosis and targeted treatment of SCLC should further enable us to attract partners to assist in bringing these promising technologies through clinical testing and on to commercialization.